Diuretic use in stage 5 chronic kidney disease and end-stage renal disease

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 5, 2003, Pages 483-490

  Sica, Domenic A ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BUMETANIDE; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOLAZONE; THIAZIDE DIURETIC AGENT; TORASEMIDE;

BULLOUS SKIN DISEASE; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIURETIC THERAPY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; EDITORIAL; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; OTOTOXICITY; PRIORITY JOURNAL; RASH; TINNITUS;

BENZOTHIADIAZINES; DIURETICS; HALF-LIFE; HUMANS; HYPERTENSION, RENOVASCULAR; KIDNEY FAILURE, CHRONIC; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 0042332243     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200309000-00001     Document Type: Editorial

References (84)

1. Russo D, Memoli B, Andreucci VE. The place of loop diuretics in the treatment of acute and chronic renal failure. Clin Nephrol 1992; 38 (Suppl 1):S69-S73.
2. Allison MEM, Shilliday I. Loop diuretic therapy in acute and chronic renal failure. J Cardiovasc Pharmacol 1993; 22 (Suppl 3):S59-S70.
3. Brater DC. Diuretic therapy. N Engl J Med 1998; 339:387-395.
4. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30:229-249.
5. Buerkert J, Martin D, Prasad J, et al. Response of deep nephrons and the terminal collecting duct to a reduction in renal mass. Am J Physiol Renal Physiol 1979; 236: F454-F464.
6. Wilcox C. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 2002; 13:798-805.
7. Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh) 1984; 54 (Suppl 1):17-29.
8. Cutler RE, Forrey AW, Christopher TG, Kimpel BM. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin Pharmacol Ther 1974; 15:588-596.
9. Beerman B, Dalen E, Lindstrom B, Rosen A. On the fate of furosemide in man. Eur J Clin Pharmacol 1975; 9:57-61.
10. Beerman B, Dalen E, Linstrom B. Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 1977; 22:70-78.
11. Huang CM, Atkinson AJ, Levin M, et al. Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 1974; 16:659-665.
12. Andreasen F, Hansen HE, Mikkelsen E. Pharmacokinetics of furosemide in anephric patients and in normal subjects. Eur J Clin Pharmacol 1978; 13:41-48.
13. Lau HSH, Hyneck ML, Berardi RR, et al. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure. Clin Pharmacol Ther 1986; 39:635-645.
14. Pentikainen PJ, Pasternak A, Lampainen E, et al. Effect of renal failure on the pharmacokinetics of bumetanide. In: Puschett JB, editor. Diuretics I: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1984. pp. 302-304.
15. Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of furosemide to bumetanide in chronic renal insufficiency. Kidney Int 1987; 32:572-578.
16. Gehr TW, Rudy DW, Matzke GR, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56:31-38.
17. Rudy DW, Gehr TW, Matzke GR, et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56:39-47.
18. Rose JH, O'Malley K, Pruitt AW. Depression of renal clearance of furosemide in man by azotemia. Clin Pharmacol Ther 1976; 21:141-146.
19. Tilstone WJ, Fine A. Furosemide kinetics in renal failure. Clin Pharmacol Ther 1978; 23:644-650.
20. Rane A, Villeneuve JP, Stone WJ, et al. Plasma-binding and disposition of furosemide in the nephrotic syndrome and uraemia. Clin Pharmacol Ther 1978; 24:199-207.
21. Andreasen F, Jakobsen P. Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure. Acta Pharmacol Toxicol 1974; 35:49-57.
22. Boobis SW. Alterations of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 1977; 22:147-153.
23. Goto S, Yoshitomi H, Miyamoto A, et al. Binding of several loop diuretics to serum albumin and human serum from patients with renal failure and liver disease. J Pharmacobiodyn 1980; 3:667-676.
24. Bowman RH. Renal secretion of [35S] furosemide and its depression by albumin binding. Am J Physiol 1975; 229:93-98.
25. Sjoholm I, Kober A, Odar-Cederlof I, Borga O. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976; 25:1205-1213.
26. Reidenberg MM. The binding of drugs to plasma proteins from patients with poor renal function. Clin Pharmacol 1976; 1:121-125.
27. Riva E, Fossali E, Bertinelli A. Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis. Eur J Clin Pharmacol 1982; 21:303-306.
28. Martin U, Winney RJ, Prescott LF. Furosemide disposition in patients on CAPD. Eur J Clin Pharmacol 1995; 48:385-390.
29. Pichette V, du Souich P. Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol 1996; 7:345-349.
30. van Olden RW, van Meyel JJM, Geriag PGG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Clin Pharmacol 1992; 12:351-356.
31. van Olden RW, van Meyel JJM, Geriag PGG. Chronic high dosage furosemide in haemodialysis patients. In: Puschett JB, editor. Diuretics III: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1990. pp. 25-27.
32. Schulz W, Dorfler A, Stiehl L, Achhammer I. Double-blind clinical trial investigating the efficacy and long-term tolerance of torasemide 200 mg p.o. compared with furosemide 500 mg p.o. and placebo p.o. in patients with chronic renal failure on hemodialysis, a multicenter study. Prog Pharmacol Clin Pharmacol 1990; 8:249-257.
33. Loute G, Adam A, Ers P, Heremans C, Willems B. The influence of haemodialysis and haemofiltration on the clearance of torasemide in renal failure. Eur J Clin Pharmacol 1986; 31 (Suppl):53-55.
34. Decourt S, Flouvat B, Goupil A, et al. Fixation proteique et demivie d'elimination du furosemide chez les hemodialyses chroniques (Protein binding and elimination half-life of furosemide in chronic hemodialysed patients) [in French]. Therapie 1979; 34:355-366.
35. Dargie HJ, Allison MEM, Kennedy AC, Gray MJB. High dosage of metolazone in chronic renal failure. BMJ 1972; 4:196-197.
36. Fliser D, Schroter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46:482-488.
37. Farthing D, Sica DA, Fakhry I, Gehr TWB. A novel HPLC method using solid phase on-line elution for determination of metolazone in plasma and whole blood. J Chromatog Biom Appl 1994; 653:171-176.
38. Sica DA. Metolazone and its role in edema management. Congest Heart Fail 2003; 9:100-105.
39. Marone C, Muggli F, Lahn W, Frey FJ. Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man. Eur J Clin Pharmacol 1985; 15:253-257.
40. Allison MEM, Kennedy AC. Diuretics in chronic renal disease: a study of high dosage furosemide. Clin Sci 1971; 41:171-187.
41. Dal Canton A, Russo D, Gallo R, et al. Muzolimine: a new high-ceiling diuretic suitable for patients with advanced renal disease. BMJ 1981; 282:595-598.
42. Morelli OH, Moledo LI, Alanis E, et al. Acute effects of high doses of frusemide in patients with chronic renal failure. Postgrad Med J 1971; 47:(Suppl):29-35.
43. Fairley KF, Laver M. High dose furosemide in chronic renal failure. Postgrad Med J 1971; 47:(Suppl):40-41.
44. Fritz KW, Wilbrandt R, Piehl W, et al. Long-term high dosage furosemide treatment in chronic renal insufficiency. Postgrad Med J 1971; 47:(Suppl):42-44.
45. Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15:90-96.
46. Cantarovich F, Galli C, Benedetti K, et al. High dose frusemide in established acute renal failure. BMJ 1973; 4:449-450.
47. Gregory Jr LF, Durrett RR, Robinson RR, Clapp JR. Short-term effect of furosemide on electrolyte and water excretion in patients with severe renal disease. Arch Intern Med 1979; 125:69-74.
48. Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982; 72:929-998.
49. Joynt MSK, Morrin PAF. Diuretic response of a severely diseased kidney to furosemide. Can Med Assoc J 1968; 99:1256-1258.
50. Levin NW. Furosemide and ethacrynic acid in renal insufficiency. Med Clin North Am 1971; 55:107-119.
51. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59:1128-1133.
52. Krediet RT, Douma CE, van Olden RW, et al. Augmenting solute clearance in peritoneal dialysis. Kidney Int 1998; 54:2218-2225.
53. Spilkin ES, Weller JM. Effect of frusemide in patients undergoing chronic intermittent peritoneal dialysis. Postgrad Med J 1971; 47:(Suppl):36-39.
54. Ouerques M, Ktena M, delli Carri P, Tappi A. The diuresis in CAPD patients. The efficacy of a loop diuretic. In: Puschett JB, editor. Diuretics I: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1984. pp. 410-412.
55. Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 1994; 9:280-286.
56. Bazzato G, Coli U, Landini S, et al. Usefulness of high dose diuretics in CAPD patients with reduced ultrafiltration capacity. In: Puschett JB, editor. Diuretics I: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1984. pp. 477-479.
57. van Olden RW, van Meyel JJ, Gerlag PG. Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur J Clin Pharmacol 1995; 47:483-488.
58. Vereestraeten PJC, Dupuis F, Toussaint C. Effects of large doses of furosemide in end-stage chronic renal failure. Nephron 1975; 14:333-338.
59. Schmidt P, Loew D, Dycka J, et al. Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis. Eur J Clin Pharmacol 1981; 20:23-26.
60. van Olden RW, van Meyel JJM, Geriag PGG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol 1992; 12:351-356.
61. van Olden RW, van Meyel JJM, Geriag PGG. Chronic high dosage furosemide in haemodialysis patients. In: Puschett JB, editor. Diuretics III: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1990. pp. 25-27.
62. van Olden RW, van Meyel JJM, Geriag PGG. Acute and long-term efficiency of high dose furosemide in hemodialysis patients with residual renal function. In: Puschett JB, editor. Diuretics III: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1993. pp. 117-120.
63. Stolear IC, Achhammer I, Georges B. Efficacy of torasemide in the treatment of patients with high-grade renal failure on dialysis. Prog Pharmacol Clin Pharmacol 1990; 8:259-267.
64. Boesken WH, Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin Nephrol 1997; 48:22-28.
65. Rybak LP. Furosemide ototoxicity: clinical and experimental aspects. Laryngoscope 1985; 95:1-14.
66. Klooker P, Bommer J, Ritz E. Treatment of hypertension in dialysis patients. Blood Purif 1985; 3:15-26.
67. Weisschedel E, Grussendorf M, Ritz E. Diuretic effect of muzolimine in advanced renal failure. Clin Nephrol 1983; 19:50-53.
68. Bennett WM, McGonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 1977; 22:499-504.
69. Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J 1983; 106:237-244.
70. Andreucci VE, DalCanton A, Conte G. Diuretic usage in chronic renal failure. In: Puschett JB, editor. Diuretics III: chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier Science; 1984. pp. 470-475.
71. Johnson CA, Grant KL, Madalon MG. Severe musculoskeletal syndrome in patients with renal failure and hypoalbuminemia receiving bumetanide. Clin Pharmacokinet 1987; 6:735-741.
72. Tuzel IH. Comparison of adverse reactions to bumetanide and furosemide. J Clin Pharmacol 1981; 21:615-619.
73. Heydenreich G, Pindborg T, Schmidt H. Bullous dermatosis among patients with chronic renal failure on high dose furosemide. Acta Med Scand 1977; 202:61-64.
74. Gilchrest B, Rowe JW, Mihm MC. Bullous dermatosis of hemodialysis. Ann Intern Med 1975; 83:480-483.
75. Burry JN, Lawrence JR. Phototoxic blisters from high frusemide dosage. Br J Dermatol 1976; 94:495-499.
76. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25:345-372.
77. Maher JF, Schreiner GE. Studies on ethacrynic acid in patients with refractory edema. Ann Intern Med 1965; 62:15-29.
78. Wigand ME, Heidland A. Ototoxic side-effects of high doses of frusemide in patients with uraemia. Postgrad Med J 1971; 47:(Suppl):54-56.
79. Ikeda K, Oshima T, Hidaka H, Takasaka T. Molecular and clinical implications of loop diuretic ototoxicity. Hear Res 1997; 107:1-8.
80. Koppel MH, Massry SG, Shinaberger JH, et al. Thiazide-induced rise in serum calcium and magnesium in patients on maintenance hemodialysis. Ann Intern Med 1970; 72:895-901.
81. Dikshit K, Vyden JK, Forrester JS, et al. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 1073; 288:1087-1090.
82. Bourland WA, Day DK, Williamson HE. The role of the kidney in the early nondiuretic action of furosemide to reduce elevated left atrial pressure in the hypervolemic dog. J Pharmacol Exp Ther 1977; 202:221-229.
83. Johnston DG, Hiatt WR, Nies AS, et al. Factors modifying the early nondiuretic vascular effects of furosemide. Circ Res 1983; 53:630-635.
84. Mukherjee SK, Katz MA, Michael UF, Ogden DA. Mechanisms of hemodynamic actions of furosemide: differentiation of vascular and renal effects on blood pressure in functionally anephric hypertensive patients. Am Heart J 1981; 101:313-318.